Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab With or Without Sorafenib in Recurrent or Metastatic Head and Neck Cancer
NCT00939627Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Started Jul 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00939627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939627.